HDAC9 and familial pancreatic carcinoma: Hence, we evaluated the anticancer potential and mechanism of a MEK inhibitor combined with our novel HDAC inhibitor MPT0E028, which currently completes phase I clinical trial for patients with solid tumors, against pancreatic cancer to provide a guide for a future developmental strategy.